Skip to content

Price / book at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
6.2×-1.0×
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
2.8×+1.0×
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
4.1×+0.5×
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
6.4×+4.6×
Biohaven logo
BiohavenBHVN
9.8×+0.4×
Septerna, Inc. logo
Septerna, Inc.SEPN
2.9×

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$24.2M+10.7%
Net income-$19.9M+17.5%
EPS (diluted)-$0.42+38.2%

Balance sheet

See full
Cash & equivalents$78.1M+35.5%
Total debt$10.8M+37.8%
Total equity$471.5M+65.0%
Total assets$497.6M+64.7%

Cash flow

See full
Operating cash flow-$13.1M+35.5%
CapEx$86.0K-70.4%
Free cash flow-$13.1M+36.0%

Valuation

See full
Market cap$1.86B+309%
Enterprise value$1.79B+352%

Returns & leverage

See full
Return on equity-28.3%
Debt / equity0.0×
Current ratio27.1×-3.9×

Where this comes from

Calculated from Rapport Therapeutics, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s price / book?
Rapport Therapeutics, Inc. (RAPP) reported price / book of 3.2× in Q1 2026.
How has Rapport Therapeutics, Inc.'s price / book changed year-over-year?
Rapport Therapeutics, Inc.'s price / book increased by 147.6% year-over-year, from 1.3× to 3.2×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.